MADISON, Wis., Sept. 19, 2017 /PRNewswire/ -- Today,
Propeller Health released the results from three new asthma and
COPD studies presented last week at the European Respiratory
Society International Congress (ERS) in Milan, Italy. The five-day event is the
world's largest respiratory health meeting.
The company shared interim results on the feasibility and
clinical impact of a digital health intervention (Propeller) among
a Medicare population with COPD. This study monitored 201
participants over a six-month period, and demonstrated a
significant decrease in short-acting bronchodilator (SABA) use and
an increase in symptom-free days.
In a second presentation, Propeller shared findings from a
two-year study investigating frequency and timing of SABA use among
3,373 asthma patients. Objective data captured from Propeller's
passive sensors illustrates how granular data on medication use can
illuminate new patterns of risk and impairment.
On Wednesday, Propeller presented data from an ongoing program
with Dignity Health, where participants experienced significant
reductions in acute asthma-related healthcare utilization,
including ED visits, hospitalization and inpatient days.
"The research presented at ERS from Dignity Health demonstrates
how Propeller may reduce the number of resource intensive events
such as asthma-related hospitalization and ED events and reduce the
disease burden for both patients and society," explained Dr.
David Stempel, Propeller SVP of
Medical and Clinical Affairs.
"We're excited to share these new data about the clinical
utility of digital health, and to take part in an active and
enthusiastic conversation in Milan
about how our technology can be put to work by physicians across
Europe," said David Van Sickle, Propeller CEO. "We look
forward to continuing to contribute to the scientific study of the
benefits of digital medicines and connected care in the management
of asthma and COPD."
Propeller has 34 peer-reviewed publications and abstracts to
date, with several studies currently in review. Propeller is
heading to Boston and Toronto next month to present at the Connected
Health Conference and the CHEST Annual Meeting.
About Propeller
Propeller empowers people with asthma and COPD to live
measurably better lives. In 2010 Propeller set out to modernize
respiratory medicine, empower people to minimize the impact of
asthma and COPD on their daily lives, and connect them to their
physicians, environment and community. Propeller's
information-powered approach to respiratory management guides
physicians and patients to the optimal path of therapy for each
individual. With connected inhalers, digital interfaces, and real
time personalized insights, participants receive personal guidance
and expert direction anytime. Backed by 3M Ventures (NYSE: MMM), SR
One, Hikma Ventures (LON: HIK), Safeguard Scientifics (NYSE: SFE),
Social Capital and other investors, Propeller has been used by
patients with asthma or COPD in over 45 commercial programs across
the US at major healthcare systems, payers, employers and other
commercial partners. The company has been recognized as the
recipient of the American Telemedicine Association's 2016
President's Award for Innovation in Remote Healthcare, as one of
the world's Most Innovative Companies by Fast Company, and as one
of the top "Fierce 15" medical device companies in 2015 by
FierceMedicalDevices. For more information visit:
www.propellerhealth.com
View original
content:http://www.prnewswire.com/news-releases/propeller-health-presents-data-on-asthma-and-copd-at-the-european-respiratory-society-international-congress-300522435.html
SOURCE Propeller Health